The efficacy of a complex of cosmetic active ingredients in melanogenesis, inflammation induced by ultraviolet rays and in brazilian subjects affected by melasma

The active complex significantly inhibited tyrosinase activity by 81.7% (p<0.001) and PGE2 synthesis up to 74%. In vivo, from 28 days, the mMASI decreased significantly by 15.8% (p<0.001), with an improvement for 58.5% of the subjects, and up to 75.6% at D140, with a decrease in mMASI of 59.6%. The subjects' quality of life was improved at D140 with a significant decrease of 52.0% in MELASQoL. Indeed, they judged the efficacy to be moderate to very significant on lightening, uniformity, prevention of new spots appearance and reduction of spots intensity and size in 63.4% to 78.0% of the cases , and moderate to very high overall efficacy in 90.2%. The product was well tolerated for 78.2% of the subjects.

By inhibiting tyrosinase activity and PGE2 UV-induced inflammation, the active complex reduces the melasma severity from 28 days after application, and thus improves the subjects’ quality of life.

Fauger A.¹, Teme B.^1,2, Weber S.¹, Cadars B.^1,2, Chavagnac-Bonneville M.^1,2, Graizeau C. ^1,2,  Trompezinski S.^1,2, and Sayag M.¹

¹NAOS, Research and Development Department, Aix-en-Provence, France

²NAOS Institute of Life Science, Aix-en-Provence, France

Fauger A.¹, Teme B.², Weber S.², Cadars B.¹, Chavagnac-Bonneville M.¹, Trompezinski S.², and Sayag M.¹

¹NAOS, Research and Development Department, Lyon, France

²NAOS, Research and Development Department, Aix-en-Provence, France